Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson Sells 5,000 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total value of $293,450.00. Following the transaction, the director now directly owns 33,611 shares in the company, valued at $1,972,629.59. The trade was a 12.95 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jeffrey William Henderson also recently made the following trade(s):

• On Monday, February 3rd, Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $56.30, for a total value of $281,500.00.
• On Monday, January 6th, Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $50.01, for a total value of $500,100.00.

Halozyme Therapeutics Trading Down 2.0 %

Shares of Halozyme Therapeutics stock opened at $57.96 on Tuesday. The firm has a market cap of $7.14 billion, a price-to-earnings ratio of 16.90, a PEG ratio of 0.42 and a beta of 1.25. The business has a 50-day moving average price of $54.53 and a 200-day moving average price of $54.72. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a twelve month low of $37.73 and a twelve month high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. The firm had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Piper Sandler raised their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. HC Wainwright raised their price target on Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Wells Fargo & Company decreased their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Finally, Benchmark reissued a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $62.78.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in HALO. Heck Capital Advisors LLC purchased a new position in Halozyme Therapeutics in the fourth quarter worth about $29,000. CBIZ Investment Advisory Services LLC purchased a new position in Halozyme Therapeutics in the fourth quarter worth about $29,000. Smartleaf Asset Management LLC grew its position in Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 197 shares in the last quarter. Venturi Wealth Management LLC purchased a new position in Halozyme Therapeutics in the fourth quarter worth about $69,000. Finally, Parkside Financial Bank & Trust grew its position in Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 322 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.